| Autor: |
Pérez JE; Grupo Oncológico Cooperativo del Sur (G.O.C.S.), República Argentina., Machiavelli MR, Romero AO, Romero Acuña LA, Domínguez ME, Fasce H, Flores Acosta L, Marrone N, Romero Acuña JM, Langhi MJ, Amato S, Bologna F, Ortiz EH, Leone BA, Lacava JA, Vallejo CT |
| Jazyk: |
angličtina |
| Zdroj: |
American journal of clinical oncology [Am J Clin Oncol] 2002 Aug; Vol. 25 (4), pp. 383-7. |
| DOI: |
10.1097/00000421-200208000-00013 |
| Abstrakt: |
A phase II trial was performed to evaluate the efficacy and toxicity of the novel combination of vinorelbine and paclitaxel as first-line chemotherapy in patients with stages IIIB and IV non-small-cell lung cancer. From January 1997 to September 1999, 34 patients (9 stage IIIB and 25 stage IV) received a regimen consisting of the following: vinorelbine 30 mg/m2 20 minutes intravenous (i.v.) infusion, days 1 and 8; and paclitaxel 135 mg/m2 3-hour i.v. (starting 1 hour after vinorelbine) on day 1. Cycles were repeated every 28 days until progression of disease or unacceptable toxicity development. The median age was 57 years (range 41-70 years); median performance status was 1. Histology was as follows: squamous cell in 24 (71%), large cell in 1 (3%), and adenocarcinoma in 9 (26%). All patients are evaluable for toxicity, whereas 30 are evaluable for response (4 patients refused treatment). Objective response was recorded in 4 of 30 patients (13%, 95% CI 1-25%). No complete response was observed. Partial response was recorded in 4 patients (13%), no change in 10 patients (34%), and progressive disease in 16 patients (53%). The median time to treatment failure was 4 months and median survival was 9 months. The limiting toxicity was myelosuppression: leukopenia in 23 patients (68%), whereas neutropenia was observed in 25 patients (78%). Peripheral neurotoxicity developed in 14 patients (41%) (without G3 or G4 episodes), and constipation (G1-G2: 10 patients), myalgia (G1-G2: 11 patients), diarrhea (G1-G2: 7 patients), and stomatitis were observed in 7 patients. Vinorelbine-paclitaxel combination showed only modest activity against locoregionally advanced or metastatic NSCLC. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
